Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet


Por: Ribrag, V, Bron, D, Rymkiewicz, G, Hoelzer, D, Jorgensen, J, de Armas-Castellano, A, Trujillo-Martín, M, Fenaux, P, Malcovati, L, Bolaños, N, Ribera, JM, Herbaux, C, Sarkozy, C, Zinzani, PL, Walewski, J and Chamuleau, MED

Publicada: 1 feb 2025 Ahead of Print: 1 feb 2025
Resumen:
Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas. Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains an area of clinical and biological research with specificities due to the high incidence of CNS involvement and tumour lysis syndrome in patients with a high tumour burden. Few consensus recommendations are available concerning diagnosis, treatment, and prognostic factors in adult patients. In this Review, a European Reference Network on Rare Haematological Diseases (ERN-EuroBloodNet) expert panel has reviewed recent advances in the management of Burkitt lymphoma in the first-line setting to develop updated evidence-based and expert opinion-based recommendations on the management of this disease. The expert panel consisted of ten clinicians and pathologists involved in the clinical management of Burkitt lymphoma from eight EU member states. Additionally, two haematologists were included to support the systematic review process. A balanced representation was ensured between individuals affiliated and not affiliated with ERN-EuroBloodNet. Together with providing current indications on diagnosis and risk-adapted first-line therapy, the Review contains specific recommendations for the identification and management of important complications of Burkitt lymphoma such as tumour lysis syndrome and CNS-oriented therapy, and recommendations for prognostic assessment to guide treatment. Finally, unresolved questions for Burkitt lymphoma are highlighted, including questions around genetics, imaging, and second-line therapies, along with patient perspective.

Filiaciones:
Ribrag, V:
 Gustave Roussy, Dept Hematol, F-94805 Villejuif, France

 Gustave Roussy, DITEP, F-94805 Villejuif, France

 Pegascy, Villejuif, France

Bron, D:
 Jules Bordet Inst, Dept Hematol, Brussels, Belgium

Rymkiewicz, G:
 Maria Sklodowska Curie Natl Res Inst Oncol, Flow Cytometry Lab, Dept Canc Pathomorphol, Warsaw, Poland

Hoelzer, D:
 Onkologikum Frankfurt, Frankfurt, Germany

Jorgensen, J:
 Aarhus Univ Hosp, Aarhus, Denmark

de Armas-Castellano, A:
 Canary Isl Hlth Res Inst Fdn, Santa Cruz De Tenerife, Tenerife, Spain

Trujillo-Martín, M:
 Canary Isl Hlth Res Inst Fdn, Santa Cruz De Tenerife, Tenerife, Spain

 Network Res Chron Primary Care & Hlth Promot, Madrid, Spain

Fenaux, P:
 Univ Paris, Dept Hematol, Hop St Louis, Paris, France

 ERN EuroBloodNet, Paris, France

Malcovati, L:
 Fdn IRCCS Policlin S Matteo, Dept Hematol Oncol, Pavia, Italy

 Univ Pavia, Dept Mol Med, Pavia, Italy

Bolaños, N:
 Lymphoma Coalit, Membership & Alliances, Barcelona, Spain

:
 ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, Dept Haematol, Barcelona, Spain

Herbaux, C:
 CHU Montpellier, Hematol Clin, Montpellier, France

Sarkozy, C:
 Univ Versailles St Quentin, Hop St Cloud, Hematol Dept, Inst Curie, Versailles, France

Zinzani, PL:
 Univ Bologna, Inst Hematol L & A Seragnoli, Bologna, Italy

Walewski, J:
 Maria Sklodowska Curie Natl Res Inst Oncol, Dept Lymphoid Malignancies, Warsaw, Poland

Chamuleau, MED:
 Amsterdam UMC, Dept Hematol, Canc Ctr Amsterdam, Amsterdam, Netherlands
ISSN: 23523026





Lancet Haematology
Editorial
Lancet Publishing Group, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Review
Volumen: 12 Número: 2
Páginas: 138-150
WOS Id: 001432079600001
ID de PubMed: 39909657
imagen Green Submitted, Green Accepted

MÉTRICAS